The Drug Development Business is Changing: “Emerging Biopharma” Driving More Commercialization

RTP Wins Q2 Solutions Expansion for Research Labs in Support of Biopharma Clinical Trials

IQVIA informs of an important  trends in clinical research and drug approvals.  Between 2005 and 2012, out of the 188 novel therapeutic agents approved by the FDA, 74 (36.8%) were approved on the basis of a single pivotal clinical trial.  The report titled “The Changing Landscape of Research and Development” evidences what we at TrialSite News have been observing for quite a while—a transforming drug development sector. 42% of novel drugs approved in 2018 were approved on the basis of only one clinical trial! The implications are considerable from costs to returns to patient choice to profit margins.
One out of 8 approvals relied on Phase 1 or 2 trials with no Phase 3 studies at all.  The studies relying on just one trial were primarily new orphan and cancer drugs—classes of treatments that can represent significant return on investment.
The IQVIA report summarizes some of the transforming elements clinical research. Back in 1997 the FDA changed the requirements allowing more flexibility with passage of the Food and Drug Administration Modernization Act.
In 2018, 59 new active substances (NAS) were launched—the highest in five years. Of this total, 12 were medicines that stratif...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee